Population
Patients susceptible to or with abdominal aortic aneurysm (AAA)
Design
Review
Key result
Osteopontin is a promising biomarker for assessing the status and progression of abdominal aortic aneurysms, while Irbesartan may reduce aneurysm size by decreasing osteoprotegrin secretion.
Loading...
Supports osteopontin as AAA biomarker but should not yet change practice; leaves open prospective validation of irbesartan effects.
Various biomarkers, particularly osteopontin, show promise in assessing AAA progression, highlighting the importance of early detection and screening.
A 2009 study conducted a review in Abdominal aortic aneurysm. Biomarkers and screening tests was evaluated. Osteopontin is a promising biomarker for assessing the status and progression of abdominal aortic aneurysms, while Irbesartan may reduce aneurysm size by decreasing osteoprotegrin secretion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: